Published in J Am Coll Surg on August 01, 1996
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
Should hepatomas be treated with hepatic resection or transplantation? Cancer (1999) 1.54
Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg (1997) 1.36
Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology (1997) 1.36
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation (2003) 1.18
A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation (1998) 1.16
Liver transplantation in the UK. World J Gastroenterol (2001) 1.02
What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl (2001) 0.93
Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation (2000) 0.92
History of clinical transplantation. World J Surg (2000) 0.91
A comprehensive review of immunosuppression used for liver transplantation. J Transplant (2009) 0.86
Urgent revascularization of liver allografts after early hepatic artery thrombosis. Transplantation (1996) 0.86
Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops. J Ocul Pharmacol Ther (2013) 0.82
Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg (1999) 0.81
Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg (1998) 0.80
Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc (1998) 0.80
Hepatic and intestinal transplantation at the University of Pittsburgh. Clin Transpl (1998) 0.78
Micro and nanoparticle drug delivery systems for preventing allotransplant rejection. Clin Immunol (2015) 0.78
Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother (2013) 0.77
The current status of hepatic transplantation at the University of Pittsburgh. Clin Transpl (1995) 0.76
Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis (1998) 0.75
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients. Hepat Med (2011) 0.75
Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. Proc (Bayl Univ Med Cent) (2011) 0.75
The mother lode of liver transplantation, with particular reference to our new journal. Liver Transpl Surg (1998) 0.75
Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant (1997) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29
A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04
Kidney transplantation under FK 506. JAMA (1990) 7.45
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med (1963) 5.14
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Kidney transplantation in modified recipients. Ann Surg (1962) 4.66
A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med (1994) 4.22
Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet (1994) 3.72
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
Randomized controlled trials in surgery. Surgery (1994) 2.53
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids. Surg Gynecol Obstet (1982) 2.42
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation (1995) 2.13
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Should we be performing more randomized controlled trials evaluating surgical operations? Surgery (1995) 2.03
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Transplantation. JAMA (1990) 1.71
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45
Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Transplant Proc (1991) 1.41
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40
A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation (1994) 1.30
Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit (1995) 0.83
A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg (1996) 0.83
Fluorescence polarization immunoassay for cyclosporine A determination in whole blood. Ther Drug Monit (1990) 0.79
Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. Transplant Proc (1992) 0.79
Evolution of liver transplantation. Hepatology (1982) 19.54
Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med (2001) 18.91
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med (1991) 18.33
The impact of patient-centered care on outcomes. J Fam Pract (2000) 15.07
A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med (2001) 13.85
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med (1998) 11.27
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
Randomization by cluster. Sample size requirements and analysis. Am J Epidemiol (1981) 9.21
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11
Kidney transplantation under FK 506. JAMA (1990) 7.45
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
WHO antenatal care randomised trial for the evaluation of a new model of routine antenatal care. Lancet (2001) 6.86
Sample size and optimal designs for reliability studies. Stat Med (1998) 6.80
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23
Small sample performance of tests of homogeneity of odds ratios in K 2 x 2 tables. Stat Med (1992) 6.20
Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet (2004) 5.93
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet (2003) 5.90
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Evaluation of a palliative care service: problems and pitfalls. BMJ (1994) 5.70
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med (2000) 4.67
Liver transplantation (1). N Engl J Med (1989) 4.53
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Developments in cluster randomized trials and Statistics in Medicine. Stat Med (2007) 4.12
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst (1999) 3.78
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55